Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PN 1007

Next Previous
X
Search
Drug Profile

PN 1007

Alternative Names: PN 1007; PPSGG

Latest Information Update: 28 Nov 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Polyneuron Pharmaceuticals
  • Class Glycopeptides; Immunotherapies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral nervous system diseases
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Peripheral nervous system diseases

Most Recent Events

  • 28 Nov 2021 No recent reports of development identified for preclinical development in Peripheral-nervous-system-diseases in Switzerland (Parenteral, Injection)
  • 15 Oct 2021 Polyneuron Pharmaceuticals terminates a phase I/II trial in Peripheral nervous system diseases (In adults, In the elderly) in France, Netherlands, Spain, Switzerland and United Kingdom, as the data failed to support further development (NCT04568174) (EudraCT2020-000067-23)
  • 23 Feb 2021 Polyneuron Pharmaceuticals suspends a phase I/IIa trial (In adults, In the elderly) in Peripheral nervous system diseases in France, Netherlands, Spain, Switzerland and the UK (IV) as initial clinical data requires further evaluation (NCT04568174)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top